• Aucun résultat trouvé

[PDF] Top 20 ‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice?

Has 10000 "‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice?" found on our website. Below are the top 20 most common "‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice?".

‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice?

‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice?

... ‘Treatment-resistanttype 2 diabetes: Which definition for clinical practice? Despite being a common feature in clinical practice and a major ... Voir le document complet

3

Pharmacological management of type 2 diabetes: what's new in 2017?

Pharmacological management of type 2 diabetes: what's new in 2017?

... in type 1 diabetes than in T2D, although caution is also required in certain circumstances in T2D ...agencies, which may limit the use of this new pharmacological class in clinical ...risk ... Voir le document complet

36

DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.

DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.

... attractive treatment options for combination ...need for specific studies for instance in insulin-treated ...DPP-4i, which opposes to the stimulatory effect on glucagon secretion ... Voir le document complet

37

Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.

Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.

... atorvastatin for several years who had recently (6 months ago) started taking ...this clinical case), which can but does not necessarily predispose to acute kidney injury (which was not the ... Voir le document complet

15

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.

... requirements for patients with confirmed calculated creatinine clearance that decreased below a specific level (this level varied across studies) and/or increases in serum ...24-week treatment period; it ... Voir le document complet

9

Voglibose for prevention of type 2 diabetes mellitus.

Voglibose for prevention of type 2 diabetes mellitus.

... drug treatment is more expensive and might be associated with adverse events (mostly gastrointestinal symptoms with α-glucosidase inhibitors, although in today's study reported as mild to moderate)? This question ... Voir le document complet

3

Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?

Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?

... Diabetes & Metabolism 40 (2014) S1-S3 Type 2 diabetes is among the most important and preva- lent chronic diseases, and any novel therapy that is able to address chronic hyperglycaemia is ... Voir le document complet

3

Pharmacological prevention of type 2 diabetes.

Pharmacological prevention of type 2 diabetes.

... for the prevention of type 2 diabetes in high-risk individuals, especially those with IGT ...in clinical practice ...modern definition of IGT and studied ... Voir le document complet

46

Type 2 diabetes mellitus and osteoarthritis

Type 2 diabetes mellitus and osteoarthritis

... metformin treatment at baseline and OA outcome during follow up (adjusted HR = ...the Clinical Practice Research Datalink; it did not find any evidence for a disease modifying osteoarthritic ... Voir le document complet

12

Preventing and treating kidney disease in patients with type 2 diabetes

Preventing and treating kidney disease in patients with type 2 diabetes

... hard clinical outcomes such as progression to ESRD or death of renal cause requires a long follow-up in large ...endpoints, which, however, may differ across RCTs ( Table 1 – 4 ...marker, for ... Voir le document complet

19

Preventing, delaying, or masking type 2 diabetes with metformin in the diabetes prevention program?

Preventing, delaying, or masking type 2 diabetes with metformin in the diabetes prevention program?

... of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, Liège, ...the Diabetes Prevention Program (DPP) showed that withdrawal of metformin for 1-2 weeks ... Voir le document complet

4

Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.

Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.

... studies, which contrasts with the unexpected interest devoted to C-peptide almost a decade ago [147,148] ...crucial for renal function in the glomeruli and ...in, for example, ... Voir le document complet

12

DPP-4 inhibitors in the treatment of type 2 diabetes.

DPP-4 inhibitors in the treatment of type 2 diabetes.

... role for GLP-1 in the cardiovascular ...mice, which spontaneously develop atherosclerosis, diminished atherosclerotic lesion size and monocyte/macrophage recruitment to the vascular wall independent of ... Voir le document complet

27

Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.

Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.

... insulin for a majority of patients with ...to which it lowers the glucose level. [43] Available data from clinical trials with dulaglutide confirm that the compound lowers both fasting and ... Voir le document complet

32

Treatment of type 2 diabetes.

Treatment of type 2 diabetes.

... with type 2 ...in type 2 diabetes, as initial therapy or most often after secondary failure to oral drug ...daily practice should include not only patient's clinical ... Voir le document complet

13

Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus

Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus

... account for the acute glucose‐lowering effect of metformin, chronic metformin‐induced AMPK activation might indirectly inhibit hepatic glucose production by increasing hepatic insulin ...sensitivity. For ... Voir le document complet

51

Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.

Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.

... 2.2 Clinical efficacy Changes in plasma glucose, insulin, and glucagon in relation to glycaemic response after a liquid meal tolerance test were analyzed during treatment with dual add-on of dapagliflozin ... Voir le document complet

44

An integrated approach for the identification of predictive markers of type 2 diabetes

An integrated approach for the identification of predictive markers of type 2 diabetes

... need for more accurate assessment of the inputs and their consequences to health (Panagiotou, ...of type 2 diabetes ...compared for several parameters (clinical, biochemical ... Voir le document complet

2

Vitamin D and type 2 diabetes mellitus: Where do we stand?

Vitamin D and type 2 diabetes mellitus: Where do we stand?

... Fig. 1. Molecular structures of (upper) vitamin D2 (ergocalciferol) and (lower) vitamin D3 (cholecalciferol). Either vitamin D2 or D3 can also be found in many pharmaco- logical supplements but, whatever the source of ... Voir le document complet

8

The endocannabinoid system: a promising target for the management of type 2 diabetes.

The endocannabinoid system: a promising target for the management of type 2 diabetes.

... The treatment with rimonabant reduced obesity-associated hepatic steatosis and features of metabolic syndrome, especially dyslipidemia, in obese Zucker fa/fa rats ...with type 2 diabetes ... Voir le document complet

49

Show all 10000 documents...